Menu Search
Equities

Suzhou Basecare Medical Corp Ltd

2170:HKG.HZ

Suzhou Basecare Medical Corp Ltd

Actions
  • Price (HKD)4.79
  • Today's Change0.07 / 1.48%
  • Shares traded8.00k
  • 1 Year change-5.89%
  • Beta--
Data delayed at least 15 minutes, as of Mar 23 2023 02:41 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Suzhou Basecare Medical Co Ltd, formerly Jiangsu Double Helix Biology Science and Technology Co Ltd, is a China-based investment holding company mainly engaged in the provision of assisted reproductive genetic testing solutions. The Company provides genetic testing solutions and sells genetic testing equipment and instruments. The genetic testing solutions include sales of testing kits and provision of testing services. The Company's main products include PGT-A kits. The Company mainly conducts business within the domestic market.

  • Revenue in HKD (TTM)143.33m
  • Net income in HKD-153.65m
  • Incorporated2010
  • Employees430.00
  • Location
    Suzhou Basecare Medical Corp LtdUnit 101, Building A3, BioBayNo. 218 Xinghu Street, Suzhou IndustrialSUZHOU 215400ChinaCHN
  • Phone+86 51 282782588
  • Websitehttps://www.basecare.cn/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.